Home - Open Targets

Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.

Find targets for a given disease
Visit the Open Targets Platform Discover genetic evidence for targets
Visit Open Targets Genetics Explore our experimental projects
Read our research publications

News

Open Targets consortium welcomes Genentech as newest member

14 November 2022

Open Targets announced today that Genentech, a member of the Roche Group, has joined the consortium, which identifies, prioritises, and validates drug targets to accelerate the development of safe and effective medicines. The second company to join the industry-academic partnership this year, Genentech will collaborate with other consortium members including EMBL’s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.